Filtered By:
Condition: Arthritis
Drug: Humira

This page shows you your search results in order of date.

Order by Relevance | Date

Total 61 results found since Jan 2013.

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years ’ experience of a tertiary pediatric rheumatology center
In this study, drug side effects in patients who were followed up with a rheumatic disease and treated with parenteral administration methods were evaluated. The drug side effects in children who were followed up with a rheumatic disease and treated with parenteral treatments between 2010 and 2019 were recorded, retrospectively. All parenteral treatments are applied by a clinical nurse specialist (CNS) who is experienced in pediatric rheumatology for 10 years. Four hundred and thirteen patients were evaluated in this study. The mean age was 12.09  ± 5.05 years. Most of them were diagnosed with juvenile idiopathic art...
Source: Rheumatology International - December 20, 2019 Category: Rheumatology Source Type: research

China ' s Bio-Thera Gets Approval for Humira Biosimilar China ' s Bio-Thera Gets Approval for Humira Biosimilar
China ' s Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc ' s blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world ' s second-largest drug market.Reuters Health Information
Source: Medscape Allergy Headlines - November 9, 2019 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Long-Term Safety and Efficacy of ABP 501 in Patients With RA Long-Term Safety and Efficacy of ABP 501 in Patients With RA
How does the safety and efficacy of the adalimumab biosimilar ABP 501 compare with that of the reference product?Arthritis Research & Therapy
Source: Medscape Allergy Headlines - May 31, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
In a large observational study, psoriasis patients lacking the susceptibility allele HLA-C*06:02 demonstrate significantly better response to adalimumab than ustekinumab. The effect is stronger than at other HLA alleles and varies with psoriatic arthritis status.
Source: Journal of Allergy and Clinical Immunology - December 19, 2018 Category: Allergy & Immunology Authors: Nick Dand, Michael Duckworth, David Baudry, Alice Russell, Charles J. Curtis, Sang Hyuck Lee, Ian Evans, Kayleigh J. Mason, Ali Alsharqi, Gabrielle Becher, A. David Burden, Richard G. Goodwin, Kevin McKenna, Ruth Murphy, Gayathri K. Perera, Radu Rotarescu Source Type: research

Adalimumab Appears Safe for Treating Pediatric Patients With Autoimmune Disease Adalimumab Appears Safe for Treating Pediatric Patients With Autoimmune Disease
Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn ' s disease (CD), according to data from company-sponsored clinical trials.Reuters Health Information
Source: Medscape Allergy Headlines - August 10, 2018 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
Despite the success of anti-TNF therapy for patients with rheumatoid arthritis (RA), around one-third of patients fail to benefit from this treatment.1 There is an intensive search for biomarkers, mostly on an empirical basis, that will guide the use of anti-TNF therapy to those patients with RA most likely to respond.2 Ineffective treatments allow inflammation to persist, resulting in joint damage and disability. A  method to predict response to anti-TNF therapy would be cost-effective and minimize delays in receiving an efficacious treatment, therefore representing a step toward precision medicine for patients with RA.
Source: Journal of Allergy and Clinical Immunology - June 20, 2018 Category: Allergy & Immunology Authors: Dao X. Nguyen, Alice Cotton, Laura Attipoe, Coziana Ciurtin, Caroline J. Dor é, Michael R. Ehrenstein Tags: Letters to the editor Source Type: research

P012 Management of ongoing adalimumab local hypersensitivity reactions after rapid subcutaneous desensitization
We present the case and management of a rheumatoid arthritis (RA) patient with large injection site reactions (ISRs) to adalimumab who underwent desensitization but continued to have ISRs.
Source: Annals of Allergy, Asthma and Immunology - October 27, 2017 Category: Allergy & Immunology Authors: F. Jiang, A. Pham, J. Yusin Source Type: research

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Conclusions Sarilumab monotherapy demonstrated superiority to adalimumab monotherapy by improving the signs and symptoms and physical functions in patients with RA who were unable to continue MTX treatment. The safety profiles of both therapies were consistent with anticipated class effects. Trial registration number NCT02332590.
Source: Annals of the Rheumatic Diseases - April 6, 2017 Category: Rheumatology Authors: Burmester, G. R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E. K., Graham, N. M. H., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., Lee, E. B. Tags: Open access, Immunology (including allergy), Pain (neurology), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Conclusions This analysis confirms and expands the known safety profile of adalimumab and reports no additional safety risk of laboratory abnormalities, hepatitis B reactivation and pregnancy outcomes, including spontaneous abortions and birth defects. The benefits of influenza vaccination are reinforced. Trial registration numbers NCT00195663, NCT00195702, NCT00448383, NCT00049751, NCT00234845, NCT00650390, NCT00235859, NCT00647920, NCT00649545, NCT00647491, NCT00649922, NCT00538902, NCT00420927, NCT00870467, NCT00650156, NCT00647270, NCT01185288, NCT01185301.
Source: Annals of the Rheumatic Diseases - January 9, 2017 Category: Rheumatology Authors: Burmester, G. R., Landewe, R., Genovese, M. C., Friedman, A. W., Pfeifer, N. D., Varothai, N. A., Lacerda, A. P. Tags: Open access, Immunology (including allergy), Travel medicine, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Conclusion LDL-C and HDL-C increased more with tocilizumab than adalimumab. HDL-SAA, sPLA2 IIA and Lp(a) decreased more with tocilizumab. Lipid change effects of interleukin-6 and tumour necrosis factor (TNF) inhibition, manifest by their net impact on lipids and lipoproteins, are not synonymous; the clinical significance is unclear and requires further study. Trial registration number NCT01119859.; post-results
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Gabay, C., McInnes, I. B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., Sattar, N. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)
Conclusions An aggressive triamcinolone and synthetic DMARD treat-to-target strategy in eRA provided excellent 2-year clinical and radiographic disease control independent of adalimumab induction therapy. ES progression was slightly less during and following adalimumab induction therapy. Trial registration number NCT00660647.
Source: Annals of the Rheumatic Diseases - August 9, 2016 Category: Rheumatology Authors: Horslev-Petersen, K., Hetland, M. L., Ornbjerg, L. M., Junker, P., Podenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzboll, C. G., Jorgensen, A., Krintel, S. B., Raun, Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13 that the agency license a biosimilar Humira (adalimumab) that is made by Amgen and a biosimilar...
Source: Skin and Allergy News - July 13, 2016 Category: Dermatology Source Type: news